Taipei, Taiwan, March 10, 2025 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical company headquartered in Taiwan, has disclosed its unaudited consolidated revenue for February 2024 of NT$967 million, with year-to-date revenue reaching NT$ 3,138 million, a 3% year-over-year increase.
February's revenue was influenced by customer stockpiling across most Asian markets ahead of the long Chinese New Year holiday, resulting in lower-than-usual monthly revenue from Asia. Additionally, export revenue declined during the month due to the postponement of all Buprenorphine/Naloxone shipments to March, allowing for critical equipment upgrades and capacity expansion.
Year to date, Lotus has achieved several significant milestones. These include the successful acquisition of Alphachymotrypsine Choay®, further solidifying its footprint in Vietnam. The company also secured market approval from the Taiwan Food and Drug Administration (TFDA) for Adcirca, which is the first and only treatment in Taiwan recommended by the ESC/ERS Guidelines as a Class I therapy in combination with endothelin receptor antagonists (ERAs) for first-line pulmonary arterial hypertension (PAH) treatment. Lotus plans to launch Adcirca in Taiwan by mid-2025, underscoring its commitment to providing innovative treatment solutions for patients.
About Lotus
Founded in 1966, Lotus (1795: TT) is a global pharmaceutical company focused on delivering novel and generic medicines that are safer, better, and more accessible. With a best-in-class R&D and manufacturing platform in Asia, Lotus has partnerships in key markets including the U.S., Europe, Japan, China, and Brazil. The company manages over 100 strategic projects in development and registration across Asia and the U.S., with a portfolio of more than 250 commercial products. Lotus invests in a diversified pipeline of high-barrier oncology treatments, complex generics, 505(b)2 products, and new chemical entities (NCEs), through internal R&D and licensing partnerships. Additionally, it bolsters its portfolio with biosimilars, supported by strategic alliances. Lotus's facilities are certified by top regulatory bodies, including the US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA.
Media Inquiries:
Yu-ying Yang, Associate Director, Corporate communication.
+886 2 2700 5908
investor@lotuspharm.com